Myocardial Metabolism in Patients With Dilated Cardiomyopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

15 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-05-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dilated cardiomyopathy (DCM) is characterized by a metabolic shift from fat to carbohydrates and failure to increase myocardial glucose uptake in response to workload increments. The investigators aimed at verifying whether this pattern is influenced by the presence of abnormal glucose tolerance (AGT).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Metabolic Characterization of Patients With Dilated Cardiomyopathy

NCT05284682

DCM - Dilated Cardiomyopathy Heart Failure

RECRUITING

Diabetic/Metabolic Cardiomyopathy: Prevalence and Phenotype

NCT05181631

Cardiopathy Diabetes Metabolic Syndrome

UNKNOWN NA

Observational Study for Patients With Dilated Cardiomyopathy

NCT04837612

DCM - Dilated Cardiomyopathy

UNKNOWN

Prognostic Values of Coronary Microvascular Dysfunction in Patients With Dilated Cardiomyopathy

NCT07293338

Dilated Cardiomyopathy (DCM)

RECRUITING

Epidemiology of Idiopathic Dilated Cardiomyopathy (Washington, DC Dilated Cardiomyopathy Study)

NCT00005262

Cardiovascular Diseases Heart Diseases Myocardial Diseases +3 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A catheter is advanced into the coronary sinus by fluoroscopy to withdraw venous blood. A unipolar pacing catheter is positioned into the right atrium. Arterial sampling is done from the femoral artery introducer catheter.

The study protocol consisted of 3 steps (Rest, Pacing and Recovery), during which timed blood samples are collected to measure plasma NEFA and glucose. After the instrumentation is completed, Rest arterio-venous sampling is performed at time -15 min and 0 min. After the 0 min, heart rate is increased by atrial pacing to 110 bpm for 3 minutes and to 130 bpm for 3 additional minutes and arterio-venous sampling is repeated at the end of each step (at time 3 and 6 min). Pacing is then stopped and at time 1, 5, 15 and 30 min into the Recovery period other pairs of arterial and venous samples are withdrawn.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dilated Cardiomyopathy Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DCM-AGT

Subjects with both dilated cardiomyopathy (DCM) and abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).

No interventions assigned to this group

DCM-NGT

Subjects with dilated cardiomyopathy (DCM) and normal glucose tolerance (NGT).

No interventions assigned to this group

N-AGT

Subjects without dilated cardiomyopathy (N) with abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For patients with dilated cardiomyopathy:

* Myocardial left ventricular ejection fraction (LVEF) \<40%
* left ventricular end-diastolic diameter (LVEDD) \>56 mm

For patients without dilated cardiomyopathy:

* LVEF \>50%
* LVEDD \<56 mm.

Exclusion Criteria

* NYHA class IV
* Atrial fibrillation
* Previous myocardial infarction
* Valvular heart disease
* Myocarditis
* Pericarditis
* Severe to moderate systemic arterial hypertension
* Fasting hyperglycaemia (\>7.0 mmol/l)
* Treated diabetes, autoimmune diseases, neoplasia, kidney, liver or respiratory failure

Minimum Eligible Age

21 Years

Maximum Eligible Age

69 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No